Search
paromomycin; aminosidine (Humatin, Gabbromicina, Gabbrora)
Indications:
- gastrointestinal infections
- adjunctive treatment to stibogluconate (Sb[V]) for visceral leishmaniasis
- treatment of cryptosporidium in patients with HIV
- Dientamoeba fragilis
- treatment of chronic intestinal amebiasis
- preoperatively used to suppress intestinal flora
- tapeworm infestations (fish, dog, bovine, porcine)
- dwarf tapeworm
- eradication of NH3-forming bacteria in hepatic coma
Dosage:
- visceral leishmaniasis
- 12-15 mg/kg/day IV or IM
- cryptosporidium in patients with HIV
- 500 to 750 mg PO TID-QID
- Dientamoeba fragilis
- 25 to 30 mg/kg/day divided TID for 7 days
- tapeworm infestations (fish, dog, bovine, porcine)
- adult: 1 g every 15 min for 4 doses
- children: 11 mg/kg every 15 min for 4 doses
- dwarf tapeworm
- children & adults: 45 mg/kg QD for 5-7 days
- eradication of NH3-forming bacteria in hepatic coma
- 4 g/day divided BID-QID for 5-6 days
Capsule: 250 mg.
Adverse effects:
1) not common (1-10%)
- diarrhea, abdominal cramps, nausea/vomiting, heartburn
2) uncommon (< 1%)
- headache, vertigo, steatorrhea, secondary enterocolitis, exanthema, rash, pruritus, ototoxicity, eosinophilia
Interactions
drug interactions
General
amebicide
aminoglycoside family
Database Correlations
PUBCHEM correlations
References
- Harrison's Principles of Internal Medicine, 14th ed.
Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 1191, 1203
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Deprecated Reference